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Abstract
Thanks to improved health standards in Iran over the past three decades, we have witnessed a shift in the causes of death in Iran from
infectious causes to non-communicable diseases—mainly cardiovascular disorders, cancers, and road trafﬁc injuries. The incidence and
prevalence of many infectious diseases, such as many parasitic infections, have fallen signiﬁcantly; there have been no reported cases of
dracunculiasis in Iran since the mid-1970s. Great strides have also been made towards the elimination of schistosomiasis in Iran. How-
ever, we still have some problems with cutaneous leishmaniasis, hepatitis C, human immunodeﬁciency virus, tuberculosis, infections
among immunocompromised hosts, hospital-acquired infections, and antibiotic-resistant bacterial strains. We need to emphasize
improvements in sanitation, good clinical practice, and education about the rational administration of antibiotics.
Keywords: Bacterial infections, communicable diseases, drug resistance, epidemiology, incidence, infection control, microbial, parasitic
diseases, prevalence, viral diseases
Article published online: 11 September 2012
Clin Microbiol Infect 2012; 18: 1081–1088
Corresponding author: M. Askarian, Department of Community
Medicine, School of Medicine, Medicinal & Natural Products Chemis-
try Research Centre, Shiraz University of Medical Sciences, Shiraz,
Iran
E-mail: askariam@sums.ac.ir
Introduction
Infectious diseases constitute a major healthcare burden for
many developing countries. Despite all of the efforts made
to control infectious diseases, it is estimated that, by the
year 2025, they will still kill almost 5 000 000 children under
5 years of age, mostly in developing countries [1].
Iran, a country with an area of 1 648 000 km2 in the Mid-
dle East, with its various climates, suffers from a wide array
of infectious diseases. Previously, the diseases were responsi-
ble for most deaths in Iran [2]; however, thanks to improved
health standards and the establishment of national surveil-
lance systems over the past two decades, we have witnessed
a shift in the causes of death in Iran from infectious causes
to non-communicable diseases—mainly cardiovascular disor-
ders, cancers, and road trafﬁc injuries [2,3]. Herein, we wish
to present a bird’s eye view of common and important infec-
tious diseases in Iran.
Viral Infections
Viral hepatitis
Viral hepatitis is more common in Iran than in western coun-
tries. Hepatitis A and B viruses are the most common causes
of acute hepatitis in children and adults, respectively. The
prevalence of hepatitis A in Iran, as in many countries in the
region, is very high, and although the age of exposure to the
virus has been increasing in Iran, owing to improved sanitary
measures, children and young adults remain the primary
targets, so that most children in Iran contract the disease
and have immunity by the age of 10 years. In most parts of
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Iran, >90% of people aged ‡33 years are seropositive for
anti-hepatitis A virus antibody [4–8].
Hepatitis B virus is the most common cause of acute hep-
atitis in adults. We have witnessed a dramatic decline in the
prevalence of hepatitis B in Iran during the last decade; the
country is now classiﬁed as a region with ‘intermediate prev-
alence’ for the disease [9]. Increased popular awareness of
hepatitis B risk factors and the establishment of a national
hepatitis B vaccination programme in 1993, which includes
vaccination of all neonates and vaccination of high-risk
groups, could be the reasons for this change. The overall
prevalence of hepatitis B surface antigen in Iran is 2.1%. Prev-
alence rates of >3% are reported in north-eastern Iran; the
rate decreases to <2% in the central and western regions
[10]. It was shown that genotype D was the only type found
in all hepatitis B surface antigen-positive patients [11,12]. The
vaccination programme has signiﬁcantly decreased the carrier
rate among young children. As a consequence, the average
age of infected people has increased [9].
In Iran, predictors of hepatitis B included family history of
the infection, history of receiving blood transfusion, hospital-
ization, unsafe sex, male gender, and living in urban areas [9].
History of surgery and imprisonment were other major risk
factors for infection [5,13]. Certain jobs [14–16] and ethnici-
ties [17] carry a higher risk of acquisition of the infection.
Approximately 1.5 million people in Iran are living with the
infection; it is estimated that 15–40% of these people are at
risk of developing cirrhosis and hepatocellular carcinoma, if
left untreated [10,18]. Hepatitis B virus is therefore a true
heathcare burden for Iran.
The overall prevalence of hepatitis C in Iran is <1% [5,19],
but the rate is much higher among multiply transfused patients
[20], including those with b-thalassaemia major [21–23] or co-
agulopathy [24], and patients with end-stage renal disease
undergoing chronic haemodialysis [25,26]. Hepatitis C virus is
the aetiology of <10% of cases of chronic hepatitis or liver cir-
rhosis. The pooled estimate of the prevalence of hepatitis C
in haemodialysis patients in Iran is 16%, with a minimum of 3%
in Isfahan province (central Iran) to a maximum of 28% in
Golestan province (north-eastern Iran) [25]. The prevalence
of the infection is also high among intravenous drug users
[19,27], but the rate has decreased with the expansion of ser-
vices for them, such as needle and syringe programmes [28].
Hepatitis C virus infection is common in kidney transplant
recipients. It is a major cause of chronic liver disease follow-
ing renal transplantation, and is associated with higher mor-
bidity and mortality rates in patients on chronic haemodialysis
[29]; it is also a major threat to allograft survival in renal
transplant recipients [26]. Although not common in the
general population, the infection imposes a great burden on
Iran, because of its serious complications and the associated
treatments.
Human immunodeﬁciency virus (HIV) infection
The prevalence of HIV infection in the 15–49-year-old age
group increased from almost 0.02% in 1990 to 0.2% in 2004,
after which the rate reached a plateau. There are almost
92 000 people living with HIV. Annually, 6000–6500 people
die of AIDS [30]. The main cause of death in patients with HIV
is tuberculosis [31]. Although patients have free access to
antiretroviral therapy, their adherence to highly active antiret-
roviral therapy, one of the most commonly used drug regimens
in Iran, does not exceed 70% [32]. One of the important
routes of transmission in Iran is sharing of syringes by intrave-
nous drug users. As HIV and hepatitis C virus are transmitted
in the same way, co-infection with these two viruses is not
uncommon. In a recent study from Shiraz, southern Iran, 78%
of 1338 studied HIV-infected patients were also infected with
hepatitis C virus, which increases the likelihood of AIDS-
related deaths by more than two-fold [33]. Another report
also showed high rates of co-infection with hepatitis B or C
virus in HIV-infected patients in Iran [34]. The co-infection
rates were signiﬁcantly higher in intravenous drug users.
Crimean–Congo haemorrhagic fever (CCHF)
Considering the descriptions of a haemorrhagic syndrome
associated with ticks in the book Zakhyre Kharazmshahi (The-
saurus of the Shah of Khwarazm) compiled by the Iranian
scholar Jorjani, CCHF may have been reported in Iran as
early as AD 1110 [35]. However, the ﬁrst evidence of the
disease in the country was presented by Chumakov et al., in
1970, when 45% of sheep sent from a Tehran abattoir to
Moscow tested positive for CCHF antigen [35]. The ﬁrst
conﬁrmed human cases of CCHF in Iran were reported in
1974 and 1975 [36]. However, it was not until the 1999 out-
break that CCHF was recognized as an important public
health problem in Iran. Between January 2000 and September
2010, 738 cases of CCHF and 108 deaths from the disease
were reported in Iran [36,37]. During this period, the dis-
ease was reported from 23 provinces of Iran; the highest
incidence rates, in descending order, were in Sistan-va-Balu-
chestan (south-eastern Iran), Isfahan (central Iran), Fars
(southern Iran), Khorasan (north-eastern Iran), and Tehran
(northern Iran). The virus isolated from Iranian patients had
the same phylogenetic characteristic as that isolated from
Pakistan (CCHF Matin strain) [38]. The maximum reported
incidence of CCHF was in 2002 [39]. However, as CCHF
presents with non-speciﬁc inﬂuenza-like symptoms, its diag-
nosis can be difﬁcult. The disease is usually transmitted
by ticks, but person-to-person transmission through close
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contact with patients or nosocomial transmission is not
uncommon [39]. There are no important reports from Iran
on other types of haemorrhagic fever.
Other emerging viral infections
A recent study of West Nile virus in the equine population
in Iran reported an overall seroprevalence of 24% (range:
1–88%), with the highest values being observed in the south-
ern and western parts of the country [40]. In another study,
of 500 blood donors tested, 5% were found to be positive
for IgG against the virus; no one tested positive for IgM [41].
In Iran, the prevalence of West Nile virus is low in patients
with encephalitis [42]. There is no information from Iran on
other emerging infections, such as Chikungunya fever, den-
gue fever, Rift Valley fever, and hantavirus infections.
Bacterial Infections
Tuberculosis
Tuberculosis was once well controlled in Iran, but, owing to
the recurrence of the disease, the appearance of drug-resis-
tant strains, and the association of tuberculosis with the HIV
pandemic (as in many parts of the world), it is becoming a
problem for Iran too. The incidence of tuberculosis in Iran is
17/100 000 population, and its prevalence is 23/100 000 pop-
ulation. It has a mortality rate of 1.8/100 000 people [43].
The distribution of the disease, however, is not uniform; the
incidence and prevalence of tuberculosis are lower in the
central parts, and higher in provinces near the country bor-
ders [44]. Co-infection with HIV is not uncommon; 27% of
patients with tuberculosis are HIV-positive. Multidrug resis-
tance is another important issue; 5% of new patients diag-
nosed with tuberculosis have multidrug-resistant tuberculosis
(MDR-TB). Approximately 52% of patients are smear-posi-
tive, 16% are smear-negative, and 29% present with extrapul-
monary involvement [43]. In a recent study, of 1742 patients
with tuberculosis, 668 (38.3%) were Afghan refugees, and
263 (15.1%) patients had MDR-TB. Factors associated with
MDR-TB included age <45 years, male sex, previous treat-
ment for the disease, immigration, poor living conditions,
and unemployment [45]. The high rate of initial resistance in
patients with MDR-TB and the high incidence of MDR-TB in
young patients could reﬂect recent transmission, which war-
rants closer monitoring of transmission trends in MDR-TB
strains.
Brucellosis
Human brucellosis is endemic in all parts of Iran [46]. The
annual incidence of the disease in Iran had fallen from >1000/
1 000 000 population in 1989 to 238/1 000 000 in 2003
[47–49]. The disease is contracted mainly by drinking raw milk
and eating soft goat cheese, and less frequently through abra-
sions of the skin, inhalation of infectious aerosols, or direct
contact of contaminated materials with the conjunctiva. The
disease is of particular importance for certain occupations, as
these routes of the infection are more important for veteri-
narians, laboratory technicians, butchers, and farmers, who
have direct contact with animals and their products, such as
blood, meat, placenta, and fetuses [50]. Person-to-person
transmission of the disease is rare. However, in cases of
transmission, the most probable route is sexual contact. Many
people in rural areas of Iran have close contact with domestic
animals, and consume raw milk and soft cheese; many children
work as shepherds, so brucellosis is endemic. Furthermore, in
some rural areas in Iran, there is a belief that, for prevention
of infection in newborns, they should be fed with raw colos-
trum, which is rich in the microorganisms if the sheep is
infected. Therefore, in many rural areas, brucellosis is an
endemic zoonotic disease in all age groups and both sexes.
Brucellosis is still a burden for Iran, not only as a healthcare
problem, but also because of the ﬁnancial loss in livestock
industries; the disease causes repeated abortions in most
infected animals [50].
Enteropathogens
Escherichia coli, Shigella and Salmonella spp. are among the
most important bacteria causing diarrhoea worldwide. In a
study in Hamedan, in the north-west of Iran, of 144 samples
collected from patients with acute diarrhoea, 11.8% were
positive for Shigella strains, and 25.7% for E. coli (10.4%
were Shiga toxin-producing E. coli); no Salmonella strains
were isolated. In 9.7% of studied patients, there was co-
infection [51]. In another study from Zahedan, Sistan-va-
Baluchestan, south-eastern Iran, of 322 paediatric patients
presenting with diarrhoea, only two (0.6%) were found to
be infected with E. coli O157:H7 [52]. Another study from
Gorgan, northern Iran, showed that 8.8% of samples taken
from 634 patients with diarrhoea were positive for Shigella
spp.; Shigella sonnei was the predominant species (55%), with
the highest frequency in summer, mostly associated with
abdominal pain and isolated from patients 2–5 years of age
[53]. One study from Shiraz, southern Iran, showed that, of
114 samples collected from 2–58-year-old patients with
diarrhoea, 9.6% were positive for Campylobacter jejuni, 15.8%
for Salmonella spp., and 9.6% for Shigella spp. The highest
prevalence of C. jejuni was observed in patients aged 11–
15 years [54].
There are reports on the emergence of antibiotic-resistant
enteropathogens. A recent study revealed that most of the
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Shigella isolates in Bushehr, southern Iran, are no longer
sensitive to tetracycline and co-trimoxazole [54]. In contrast
to previous reports from Iran [55], which showed that all of
the Salmonella Typhi isolates were pan-susceptible to the
antibiotics used, a recent study revealed a high frequency of
multidrug resistance in many Salmonella isolates recovered
from patients admitted to six different hospitals in Tehran,
northern Iran [56].
Helicobacter pylori
Helicobacter pylori has an important role in the pathophysiol-
ogy of peptic ulcer disease and the development of gastric
metaplasia and gastric cancer [57]. Therefore, the infection
may impose an indirect heath burden in a country where
gastric cancer is common. In Iran, the prevalence of infection
is 40.9% in the 7–18-year age group, 68% in the 19–45-year
age group, and 75.6% in the ‡45-year age group.
Chlamydial infection
The prevalence of chlamydial infection in north-eastern Iran
is high; of 178 male patients presenting with urethritis in
Mashhad, 10.7% were infected with Chlamydia trachomatis
[58]. There is a high prevalence of Chlamydia trachomatis
infection among women with cervicitis in Tehran; 49% of
31–40-year-old patients and 33% of 20–30-year-old patients
were positive for the infection [59].
Leptospirosis
With an incidence rate of 1.6/100 000 people per year, lep-
tospirosis is not uncommon in Mazandaran province, north-
ern Iran, where rice cultivation ﬁelds are abundant [60]. The
disease is mainly occupational [61], and is typically seen in
40–59-year-old male farmers during summer.
Q-fever
There is little information on human Q-fever in Iran. A
recent study conducted in south-eastern Iran on febrile
patients with suspected brucellosis reported Coxiella burnetii
phase I and II speciﬁc IgG in 24% and 36% of patients,
respectively [62]. Another study reported the ﬁrst molecular
detection of Coxiella burnetii in ticks collected from domestic
animals in Kerman Province, south-eastern Iran [63].
Listeriosis
There is little information on the epidemiology of listeriosis
in Iran. In a study conducted in 1989 in Teheran, 1–11% of
children were found to be seropositive against one of differ-
ent serotypes of Listeria [64]. A recent case–control study
on women of child-bearing age revealed that 36% of those
with a history of spontaneous abortion and 18% of those
with normal full-term deliveries were positive for Listeria
monocytogenes antibody [65].
Parasitic Infections
Over the last four decades, we have witnessed a signiﬁcant
fall in the prevalence rates of many helminthic infections in
general, and of some of the intestinal nematodes in particu-
lar. For example, the prevalence of human ascariasis in Maz-
andaran province, northern Iran, fell from 86.3% in 1961 to
merely 0.3% in 1995 [66,67]. The overall prevalence of Asca-
ris lumbricoides in Iran is 1.5%; the highest rate of >23% was
reported from north-western regions. Hookworms have a
low prevalence rate of <0.1% in Iran. Trichostrongylus has a
pooled prevalence of 0.2%, with the highest rate reported
from Khuzestan, in the north of the Persian Gulf. Trichuris
trichiura and Taenia saginata have prevalence rates of 0.1%
and 0.2%, respectively [68]. There have been no reported
cases of dracunculiasis in Iran since the mid-1970s. Great
strides have also been made towards the elimination of
schistosomiasis in Iran [68,69]. However, some helminthic
diseases, especially those with a direct faecal–oral route of
transmission, such as that caused by Enterobius vermicularis,
remain common in many parts of Iran. The reported preva-
lence of the disease ranges from 9% in the south-western
region to 35% in Urmia, in the north-west [68]. In a nation-
wide survey of the prevalence of intestinal parasitic infections
in Iran, of 53 995 people aged >2 years, 19.3% had intestinal
parasitic infections. Giardia lamblia (10.9%), A. lumbricoides
(1.5%), Entamoeba histolytica (1.0%) and Enterobius vermicularis
(0.5%) were the most common parasites isolated [70]. The
prevalence was highest in the 2–14-year-old age group
(25.5%) and in rural areas (23.7%).
Giardiasis is the most common parasitic infection in Iran.
In a national study, the pooled prevalence was 18.3% in the
2–14-year-old age group, 12.3% in the 15–39-year age group,
and 9.7% in the 40–69-year age group [71]. The prevalence
in rural areas (15.4%) was slightly higher than that in urban
areas (13.7%). Males were more affected than females (15.1%
vs. 13.9%) [71]. The peak prevalence was observed in boys
aged 10–12 years and girls aged 8–10 years. In some cities in
the Caspian littoral, northern Iran, the prevalence was 70%
in males and 30% of females. In hyperendemic areas, the
infection may even be observed in neonates [72].
Echinococcosis
Echinococcus granulosus is hyperendemic in Iran; the disease
prevalence was increased by an inﬂux of infected Afghan
refugees. Between 5% and 50% of the stray or sheep dogs
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studied in various parts of Iran were infected with adult
Echinococcus granulosus [68,73,74]. In Iran, three distinct life
cycles have been suggested: a domestic cycle between dogs
and livestock, a desert cycle between dogs and camels, and a
sylvatic cycle between wild carnivores and wild ruminants
[74]. Echinococcus multilocularis is rare in Iran.
Fascioliasis
Two decades ago, fascioliasis was considered to be an
important chronic disease in the Caspian littoral, northern
Iran [68,75]. Between 1999 and 2002, 107 patients from this
region were found to be infected with Fasciola. The infection
has been linked to frequent ingestion of potentially contami-
nated aquatic plants. In 2000, there was also a report of 17
cases of non-fatal fascioliasis in the western province of Ker-
manshah [76]. The infection was found in 1.5% of the local
cattle; the source of the human infections was believed to be
consumption of contaminated watercress [76].
Leishmaniasis
The cutaneous form of the disease is the most common
form of leishmaniasis in Iran [69]. Mucocutaneous leishmania-
sis (espundia) is extremely rare in Iran [77]. However, there
are foci of visceral leishmaniasis (kala-azar), mainly in south-
ern and western parts of the country [78]. With the spread
of HIV, the disease has become increasingly prevalent, and
unusual presentations often occur [79]. The most common
causes of the disease in Iran are Leishmania tropica and Leish-
mania major [80,81]. The vector for anthroponotic cutaneous
leishmaniasis is Phlebotomus sergenti; for zoonotic cutaneous
leishmaniasis, the vectors are Phlebotomus papatasi and
Phlebotomus caucasicus [78].
Malaria
The high frequency of haemoglobinopathies in Iran is evi-
dence for the existence of malaria in ancient times in Iran
[82], but the country is now in the pre-elimination phase;
according to a recent WHO report, there are 564 active
foci of malaria in Iran. These foci are mainly in the south-
eastern parts of the country. More than 95% of all malaria
patients live in these areas, including Sistan-va-Baluchestan
province, Hormozgan province and tropical parts of Kerman
province. Only 3% of Iranians live in these regions [83]. The
annual incidence of malaria in Iran was estimated to be 0.14–
8.74/1000 people in 2010 [84]. According to the WHO,
there were almost 70 000 conﬁrmed cases of malaria in Iran
in 2010 [85]. The major Plasmodium spp. in Iran are Plasmo-
dium falciparum and Plasmodium vivax; the most important
vectors are Anopheles stephensi, Anopheles culicifacies, Anophe-
les ﬂuviatilis, and Anopheles superpictus [83].
Nosocomial Infections
Hospital-acquired infections (HAIs) constitute one of the
most important healthcare burdens in Iran, and are mostly
preventable [86]. According to National Nosocomial Infec-
tions Surveillance data collected between 2007 and 2010
from 100 hospitals with >200 beds, among 6 616 520 stud-
ied patients, the most common HAIs were urinary tract
infections (28.9%), pneumonia (28%), surgical site infections
(26.8%), and bloodstream infections (16.4%). HAIs were
most prevalent in burns wards, followed by intensive-care
units, and haematology/oncology wards. The overall mortality
rate among patients with HAIs was 14.8% [87].
In a recent study conducted in southern Iran on 3450
patients, the overall prevalence of HAIs was 9.4%; the most
common HAIs were bloodstream infections (2.5%), surgical
site infections (2.4%), urinary tract infections (1.4%), and pneu-
monia (1.3%) [88]. Use of a central intravenous catheter, hav-
ing a urinary catheter and hospital stays of >8 days were
independent risk factors for the development of HAIs. Being
admitted to an intensive-care unit was not an independent risk
factor for the development of HAIs. There was a high discrep-
ancy between the development of HAIs and antibiotic use.
Whereas 71% of the patients were treated with antibiotics,
only 9.4% of them also had at least one documented infection
[88]. Both the type of infection and the causative organism
depend on the ward and the procedure performed. Whereas
the most common HAI in patients admitted to an intensive-
care unit was ventilator-associated pneumonia, mostly caused
by Acinetobacter baumannii, Staphylococcus aureus (both methi-
cillin-resistant and methicillin-sensitive), and Pseudomonas aeru-
ginosa [89], the most common HAI in patients admitted for
elective open-heart surgery was surgical site infection [90]. In
another study on patients admitted to an intensive-care unit in
northern Iran, urinary tract infection caused by Klebsiella spp.
was the most common HAI [91].
With the introduction of transplantation and the increase in
longevity of immunocompromised patients, one of the challeng-
ing problems is management of infection in these patients [92].
Invasive fungal infections, usually caused by Aspergillus spp., Mu-
corales spp., Candida spp., and Cryptococcus neoformans, are
important causes of mortality in transplant patients in Iran [93].
Antibiotic Resistance
Another important health burden for Iran is antibiotic resis-
tance, which is, in fact, a global health problem; the burden
of antibiotic resistance is mainly borne by developing coun-
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tries. Irrational use of antibiotics causes the development of
resistant bacterial strains [94]. The three most commonly
prescribed antibiotics in 2001 were amoxycillin, co-trimoxaz-
ole, and ampicillin [95]. Currently, the most commonly used
antibiotics include ceﬁxime, ceftriaxone, ciproﬂuoxacin,
amoxycillin–clavulanic acid, and azithromycin. Iranian physi-
cians, like many of those practising in the region, might pre-
scribe antibiotics for the treatment of non-bacterial
infections, such as viral infections, for which antibiotics are
completely useless [94]. In Iran, the irrational use of antibiot-
ics is not restricted to humans. Antibiotics are reportedly
overused in veterinary medicine and the poultry and ﬁshery
industries too; this leads to the emergence of resistant
microbial strains in animals, and the spread of such strains to
people through the food chain [96].
The prevalence of antibiotic-resistant bacteria in Iran is high.
In a recent study, 10.23% of >25 000 blood cultures examined
over a period of 5 years were positive for bacterial growth, and
46.7% of the organisms were Gram-positive bacteria. Among
the Gram-positive bacteria recovered, 79% were methicillin-
resistant S. aureus [97]. Another study, conducted in a teaching
hospital in Tabriz, north-western Iran, reported that 63% of Aci-
netobacter baumannii isolates collected from various clinical
specimens were resistant to carbapenems, the antibiotics that
are considered to be the last available line of defence against
many Gram-negative bacteria [96,98]. Another study, in Ahwaz,
south-western Iran, revealed that 38% of P. aeruginosa strains
isolated from 100 burns patients were multidrug-resistant; 41%
of the isolates were resistant to carbapenems [99]. There also
reports of multidrug-resistant Salmonella spp. [56].
Islam is the prevailing religion in Iran. Every year, a large
number of people from Iran go to Saudi Arabia to take part
in the Hajj ritual, which is another important issue to be
considered in the control of infectious diseases. In mass gath-
erings such as the Hajj, antibiotic-resistant strains can easily
be spread to the region or other continents by international
travellers. Every year after the return of pilgrims from the
Hajj, physicians in Iran face several new infectious dis-
eases—mainly ﬂu-like syndromes [96,100].
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